Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
Bianca RaffaelliRoberto De IccoMichele CorradoMaria TerhartJessica AilaniPublished in: Cephalalgia : an international journal of headache (2023)
The open-label study program for calcitonin gene-related peptide-targeted migraine preventives confirms the favorable safety and efficacy profile of these drugs over time. Treatment adherence appears higher than with previous unspecific migraine preventives. Real-world data and post-marketing surveillance studies may corroborate and complement open-label results.